# Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

> **NCT04271202** · PHASE4 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 64 (actual)

## Conditions studied

- Chronic Migraine

## Interventions

- **DRUG:** Emgality 120 MG in 1 ML Prefilled Syringe

## Key facts

- **NCT ID:** NCT04271202
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2023-11-22
- **Final completion:** 2023-11-22
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271202, "Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04271202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*